.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020786

« Back to Dashboard
NDA 020786 describes ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from six suppliers. There are four patents protecting this drug. Additional details are available on the ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION profile page.

The generic ingredient in ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is fexofenadine hydrochloride; pseudoephedrine hydrochloride. There are twenty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the fexofenadine hydrochloride; pseudoephedrine hydrochloride profile page.

Summary for NDA: 020786

Pharmacology for NDA: 020786

Suppliers and Packaging for NDA: 020786

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL 020786 NDA sanofi-aventis U.S. LLC 0088-1090 0088-1090-47 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0088-1090-47)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL 020786 NDA sanofi-aventis U.S. LLC 0088-1090 0088-1090-49 100 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0088-1090-49)

Summary for product number 002

Active Rx/OTC/Discontinued:OTCDosage:TABLET, EXTENDED RELEASE;ORALStrength60MG;120MG
Approval Date:Jan 24, 2011TE:RLD:Yes
Patent:5,855,912*PEDPatent Expiration:Aug 28, 2015Product Flag?Substance Flag?Delist Request?
Patent:6,037,353*PEDPatent Expiration:Sep 14, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:6,039,974Patent Expiration:Jul 31, 2018Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 020786

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 20117,138,524*PED► subscribe
Sanofi Aventis Us
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 20115,578,610*PED► subscribe
Sanofi Aventis Us
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 20116,187,791*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc